A Case of Severe Pneumocystis Pneumonia in a Thyroid Cancer Patient Receiving Lenvatinib
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for use in patients with iodine-131–refractory thyroid cancer. The common adverse events of lenvatinib include hypertension, proteinuria, fatigue, and diarrhea. To date, no report on Pneumocystis pneumonia (PCP) in patients receiving lenvatinib has been published. Here, we present a case of severe PCP that led to the death of a 79-year-old woman who was diagnosed with poorly differentiated thyroid cancer and received lenvatinib. The development of PCP should be considered when patients taking lenvatinib show clinical symptoms of pneumonia, and regular chest X-ray follow-up is needed for patients receiving lenvatinib.
Abstract
Lenvatinib is a multitargeted tyrosine kinase inhibitor approved for use in patients with iodine-131–refractory thyroid cancer. The common adverse events of lenvatinib include hypertension, proteinuria, fatigue, and diarrhea. To date, no report on Pneumocystis pneumonia (PCP) in patients receiving lenvatinib has been published. Here, we present a case of severe PCP that led to the death of a 79-year-old woman who was diagnosed with poorly differentiated thyroid cancer and received lenvatinib. The development of PCP should be considered when patients taking lenvatinib show clinical symptoms of pneumonia, and regular chest X-ray follow-up is needed for patients receiving lenvatinib.
참고문헌 (10)
- Valerio L, "Targeted therapy in thyroid cancer: state of the art", Clin Oncol (R Coll Radiol), 29(5), pp.316~324 (2017)
- Schlumberger M, "Lenvatinib versus placebo in radioiodinerefractory thyroid cancer", N Engl J Med, 372(7), pp.621~630 (2015)
- Thomas CF Jr, "Pneumocystis pneumonia", N Engl J Med, 350(24), pp.2487~2498 (2004)
- Truong J, "StatPearls" (2019), StatPearls Publishing
- French JD, "Leveraging the immune system to treat advanced thyroid cancers", Lancet Diabetes Endocrinol, 5(6), pp.469~481 (2017)
- Tasaka S, "Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies", J Infect Chemother, 18(6), pp.793~806 (2012)
- Liu Y, "Risk factors for mortality from pneumocystis carinii pneumonia (PCP) in non-HIV patients: a meta-analysis", Oncotarget, 8(35), pp.59729~59739 (2017)
- Ibrahimpasic T, "Poorly differentiated carcinoma of the thyroid gland: current status and future prospects", Thyroid, 29(3), pp.311~321 (2019)
- Shah RR, "Tyrosine kinase inhibitor-induced interstitial lung disease: clinical features, diagnostic challenges, and therapeutic dilemmas", Drug Saf, 39(11), pp.1073~1091 (2016)
- Kotani K, "Interstitial pneumonia suspected during regorafenib administration and exacerbated by subsequent therapy with lenvatinib for unresectable hepatocellular carcinoma", Clin J Gastroenterol, 12(4), pp.355~360 (2019)